The oncoprotein HER-2/neu is a prosurvival factor, and its overexpression has been correlated with poor prognosis in patients with breast cancer. We report that HER-2 is a new substrate for caspase-8 and that tumor necrosis factor ␣ (TNF-␣) stimulation leads to an early caspase-8-dependent HER-2 cleavage in MCF7 A/Z breast adenocarcinoma cells defective for nuclear factor B (NFB) activation. We show that the antiapoptotic transcription factor NFB counteracts this cleavage through induction of the caspase-8 inhibitor c-FLIP. Our results also demonstrate that this HER-2 cleavage contributes to the TNF-␣-induced apoptosis pathway because ectopic expression of an uncleavable HER-2 protects NFB-defective cells against TNF-␣-mediated cell death. Therefore, we propose an original model in which NFB exerts a new antiapoptotic function by counteracting TNF-␣-triggered cleavage of the HER-2 survival factor.
INTRODUCTION
Tumor necrosis factor ␣ (TNF-␣) plays a pivotal role in the control of cell proliferation and inflammation by regulating proapoptotic and antiapoptotic signaling pathways through binding to two distinct receptors, TNF receptor 1 (TNF-R1) and TNF receptor 2 (TNF-R2; Refs. [1] [2] [3] [4] [5] . TNF-␣ binding triggers receptor trimerization and subsequent recruitment of various signaling proteins to the receptor cytoplasmic domains. Depending on the nature of the receptor and the adaptor proteins, TNF-␣ can exert opposite effects (6 -8) . Activation of the TNF-R2 produces an antiapoptotic and proinflammatory cascade, whereas activation of the TNF-R1 leads to antagonist events, namely, apoptosis through recruitment and activation of caspase-8 (9) as opposed to the activation of the antiapoptotic and proinflammatory transcription factor nuclear factor B (NFB; Refs. 6 -8) . Numerous NFB target genes counteract the TNF-␣-activated apoptosis pathway and include caspase inhibitors such as c-IAP1 (10), c-IAP2 (11, 12) , XIAP (13) , and c-FLIP (14) ; Bcl-2 family members such as A1 (15) (16) (17) or Bcl-x L (18, 19) ; and other proteins like A20 (20 -22) or MnSOD (23) (24) (25) . These opposite events can explain that TNF-␣ is a poor inducer of apoptosis in the absence of RNA or protein synthesis inhibitors (26 -28) .
Cancers are characterized by an increased proliferation and a decreased apoptotic rate (29) . Among the proteins implicated in this dysregulation, HER-2/neu (ErbB-2) plays a major role in some ovarian and breast cancer cells. The Her-2 oncogene encodes a transmembrane receptor protein structurally related to the epidermal growth factor receptor (30, 31) . HER-2 is overexpressed in approximately one-third of the primary breast carcinomas (32) and in ovarian carcinomas (31, (33) (34) (35) , and its expression is correlated with poor prognosis and decreased overall and disease-free survival (36 -38) . HER-2 overexpression has been demonstrated to enhance proliferative, metastatic, and prosurvival signals in breast cancer cell lines (39 -41) and to induce resistance to hormonal therapy, paclitaxel, and TNF-␣ (31, 39, 42, 43) , although one report did not find any modification of TNF response in relation with HER-2 expression (44) . Moreover, the anti-HER-2 antibody trastuzumab has clinical activity either alone or combined with chemotherapy in HER-2-expressing breast cancers (45) (46) (47) (48) (49) (50) .
Because the link between HER-2 overexpression and NFB currently is unclear, we studied the effect of TNF-␣ treatment and NFB activation on HER-2 expression in MCF7 A/Z breast adenocarcinoma cells. We demonstrated that TNF-␣ stimulation leads to HER-2 cleavage through a caspase-8-dependent pathway in cells defective for NFB activation. Therefore, our results provide evidence for HER-2 being a newly described caspase-8 substrate and demonstrate that NFB-dependent inhibition of HER-2 cleavage could be a novel mechanism for NFB antiapoptotic role.
MATERIALS AND METHODS
Reagents. Human recombinant TNF-␣ was purchased from Roche (Mannheim, Germany). Cycloheximide and actinomycin D were from Sigma (St. Louis, MO), and BAY 11-7085 was obtained from Biomol (Plymouth Meeting, PA). Recombinant caspase-8 and caspase inhibitors were purchased from Calbiochem (La Jolla, CA).
Cell Cultures and Transfections. MCF7 A/Z breast cancer cells (supplied by Dr. Mareel, University of Ghent, Belgium) were maintained in RPMI 1640 medium without phenol red supplemented with 10% stripped fetal bovine serum, 1% L-glutamine (200 mM), penicillin (100 IU), and streptomycin (100 g/ml). For the stably transfected cell lines (pcDNA3 and IB␣ MT), culture medium was supplemented with geneticin (G418, 500 g/ml; Roche).
For DNA transfection, cells were plated at 7 ϫ10 5 cells per 35-mmdiameter well culture dishes and transfected 24 h later with FuGENE, according to the protocol provided by the manufacturer (Roche).
Protein Extraction and Western Blot Analysis. Whole cell extracts were obtained by resuspending the PBS-washed cellular pellets in SDS 1%. The lysates then were boiled for 10 min, and protein amounts were quantified with Micro BCA Protein Assay reagent (Pierce, Rockford, IL) using a BSA standard solution as reference.
Protein extracts were separated on SDS-PAGE gels and blotted onto an Immobilon P membrane (polyvinylidene diflouride; Millipore, Bedford, MA). The membranes then were blocked in Tris-buffered saline/Tween 20% buffer plus 5% nonfat dry milk, incubated for 2 h with the first antibody, washed with Tris-buffered saline/Tween 20%, and incubated for 1 h with the second horseradish peroxidase-conjugated antibody (DAKO, Glostrup, Denmark). The reaction was revealed with the enhanced chemoluminescence detection method (ECL kit; Amersham Pharmacia Biotech, Piscataway, NJ).
The following antibodies were used for Western blot analysis: rabbit poly-clonal anti-HER-2 (Upstate Biology, Lake Placid, NY), mouse monoclonal antiactin (Sigma), mouse monoclonal anti-poly(ADP-ribose) polymerase (PARP; PharMingen, San Diego, CA), and mouse monoclonal XIAP (R&D, Minneapolis, MN). Mouse monoclonal anti-c-FLIP (sc-5276), rabbit polyclonal anti-c-IAP-1 (sc-7943), and anti-c-IAP-2 (sc-7944) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Real-Time Quantitative PCR. Total RNA was extracted using RNeasy columns from Qiagen (Valencia, CA) according to the manufacturer's recommendations. After DNase treatment, RNAs were eluted and quantified using a spectrophotometer. One g of RNA then was reverse transcribed using the first-strand cDNA synthesis kit for reverse transcription-PCR (Roche).
The quantitative PCR reaction samples involved 2 l of 20ϫ diluted cDNAs, 2 l of 10ϫ SYBR Green PCR mix buffer, 1.6 l MgCl 2 25 mM and 7 M of each primer. The number of cycles was selected to allow linear amplification of the cDNAs under study. For quantitative PCR, the GAPDH housekeeping gene was used as a control. Quantification was performed with the LightCycler PCR Technology (Roche). The primer sequences were as follows: GAPDH, 5Ј-ATGGGGAAGGTGAAGGTGGTC-3Ј and 5Ј-TGATG-GCATGGACTGTGG-3Ј; and HER-2, 5Ј-AGACGAAGCATACGTGA-3Ј and 5Ј-GTACGAGCCGCACATC-3Ј.
Caspase-8 Activity.
To evaluate caspase-8 activity, pcDNA3 MCF7 A/Z cells pretreated or not with cycloheximide (CHX) and IB␣ MT cells were stimulated with TNF-␣. Cell lysates then were incubated for 3 h at 37°C with a caspase-8 fluorogenic substrate, Ac-IEPD-AMC (Alexis Biochemicals, Lausen, Switzerland). The fluorescence of the generated cleaved product then was measured using a spectrofluorometer (380 nm and 460 nm). The experimental procedure followed the manufacturer's recommendations.
FLIP Antisense Experiments. FLIP antisense, 5Ј-ACTTGTCCCTGCTC-CTTGAA-3Ј; sense, 5Ј-TTCAAGGAGCA GGGACAAGT-3Ј; or scrambled, 5Ј-ATCACGTATCGTCGCTTCTC-3Ј oligonucleotides bearing phosphorothioate linkages were delivered into cells by lipofection with FuGENE (Roche) at a final concentration of 10 M for 8 h before TNF-␣ treatment.
Generation of HER-2 Mutants. We screened the HER-2 amino acid sequence for aspartate residues and identified six putative caspase-8 cleavage sites. For each site, we mutated the aspartate residue into an alanine using the Quick Change XL site-directed mutagenesis kit (Stratagene, Cedar Creek, TX) following the manufacturer's instructions. Twenty-seven nucleotide-long oligonucleotides carrying a single nucleotide mutation in the middle were generated in this purpose, and the mutations were GCT (A) instead of GAT (D) for the mutations D837A, D1012A, D1019A, D1087A, and D1125, and GCC (A) instead of GAC (D) for the mutation D115A.
In Vitro Proteolysis Assays. In vitro proteolysis assays were performed as described previously (51) . HER-2 coding sequence (a gift from Dr. Di Fiore, Bethesda, MD) was subcloned by PCR in a PCR-XL-TOPO vector using the TOPO XL PCR cloning kit (Invitrogen, Carlsbad, CA). This plasmid was mutated in vitro using the Quick Change XL site-directed mutagenesis kit (Stratagene) following the manufacturer's instructions.
C-termini were amplified by PCR and translated in vitro in the presence of [ 35 S]methionine using the TNT T7 Quick for PCR DNA kit (Promega, Madison, WI) and incubated with recombinant caspase-8 (100 units) or cellular extracts (50 g) at 37°C for 2 h.
After TNF-␣ stimulation, cells were harvested, washed with PBS, and centrifuged. The cellular pellets then were resuspended in hypotonic buffer (10 mM HEPES, 40 mM glycerophosphate, 50 mM NaCl, 2 mM MgCl 2 , 5 mM EGTA, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, and 0.5 g/ml aprotinin). After freezing and thawing, the lysates were cleared by centrifugation. The extracts were incubated in the presence of the 35 S-labeled HER-2 C-termini with or without a 15-min pretreatment with caspase-8 inhibitor. The samples then were boiled and analyzed by SDS-PAGE.
Thymidine Incorporation. MCF7 A/Z IB␣ cells were seeded in 96-well plates (5000 cells/well). Twenty-four h later, cells were transfected with the pcDNA3 empty vector or with an expression vector coding for HER2 WT or MT. Twenty-four h after transfection, [H 3 ]thymidine (0.4 Ci/well; Sigma) was added in the culture medium, and cells were incubated for 5 h. Cells then were lysed, and DNA was transferred on a Unifilter GC plate (Perkin Elmer, Boston, MA) using a Packard Filter Mate. After plate drying, Microscint O (Perkin Elmer) was added, and [H 3 ]thymidine incorporation was assessed using a microplate scintillation counter (Top count; Perkin Elmer).
RESULTS

TNF-␣-Mediated HER-2 Degradation in NFB-Defective Cells.
To study the effects of TNF-␣ and NFB on HER-2 expression levels, we used MCF7 A/Z mammary adenocarcinoma cells stably transfected either with an empty vector (pcDNA3 or control cells) or with an expression vector encoding IB␣ mutated on serines 32 and 36 (IB␣ MT or MT cells), an NFB super-repressor that inhibits NFB nuclear translocation and biological activity and leads to increased apoptotic response to TNF-␣ (52).
Both cell lines were stimulated with TNF-␣ for up to 24 h. HER-2 expression was investigated by Western blot analysis and remained constant in the control cell line. By contrast, an important decrease of HER-2 levels was observed in the cell overexpressing the mutated form of IB␣ (Fig. 1) .
To determine the influence of transcriptional regulation on decreased HER-2 protein, MCF7 A/Z pcDNA3 or IB␣ MT was treated with TNF-␣ for 2 or 4 h, and levels of HER-2 transcripts were assessed by quantitative real-time PCR using HER-2-specific primers and GAPDH housekeeping gene as controls. No difference in HER-2 mRNA levels was observed when both cell lines were stimulated by TNF-␣ ( Fig. 2A) . Moreover, TNF-␣ did not modify the transcriptional activity on the HER-2 proximal promoter as judged by luciferase assays (data not shown). To inhibit RNA neosynthesis, control and IB␣ MCF7 A/Z cells were preincubated with actinomycin D for 1 h before a TNF-␣ time course stimulation and real-time PCR experiment were performed with HER-2 and GAPDH primers. We observed that the degradation rate of HER-2 mRNA was identical in both cell lines (Fig. 2B) . Therefore, these results demonstrate that in our experimental conditions, TNF-␣-mediated HER-2 down-regulation was not the consequence of decreased RNA levels.
To investigate whether a difference in HER-2 protein stability was involved in the TNF-␣-mediated HER-2 disappearance in IB␣ MT MCF7 cells, we first incubated both cell lines with CHX before TNF-␣ stimulation. HER-2 protein levels were assessed using Western blot analysis. In both cell lines, HER-2 protein was not detectable beyond 4 h of TNF-␣ stimulation (Fig. 3A) . However, HER-2 protein is highly stable because we detected its expression Ͼ24 h after CHX alone in both cell lines (Fig. 3B and data not shown) .
TNF-␣-stimulated control cells then were preincubated with CHX or BAY 11-7085, a NFB inhibitor, and HER-2 protein levels were assessed by Western blot analysis. In agreement with our previous results, we observed a decrease in HER-2 protein levels in response to TNF-␣ only after NFB or protein synthesis inhibition (Fig. 3B) , indicating that an NFB-dependent protein synthesis occurs in MCF7 A/Z control cells and counteracts the TNF-␣-mediated HER-2 degradation. HER-2 Cleavage by ␣-Activated Caspase-8 in NFB-Defective Cells. We hypothesized that decreased HER-2 levels in response to TNF-␣ might be a consequence of protease activation. To test such a hypothesis, we preincubated cells with protease inhibitors and tested their ability to counteract the TNF-␣-mediated HER-2 decay. Phenylmethylsulfonyl fluoride (a serine protease inhibitor) and hydroxamate (a specific inhibitor of some metalloproteases) did not prevent HER-2 degradation in response to TNF-␣ stimulation in cells overexpressing the mutated IB␣ (data not shown).
Because it has been demonstrated recently that HER-2 may be a caspase substrate in geldanamycin and staurosporin-treated cells, we investigated this pathway (53) . We observed endogenous caspase-8 cleavage and activation following TNF-␣ stimulation in MT cells and CHX-pretreated control cells (Fig. 4, A and B) , and the kinetics of this activation perfectly paralleled HER-2 decay and PARP cleavage (compare Fig. 4 and Fig. 5) .
Moreover, z-IETD-fmk, a specific caspase-8 inhibitor, blocked TNF-␣-and CHX-induced HER-2 degradation in control cells, whereas caspase-3 or caspase-9 inhibitors did not have any effect (Fig.  5A and data not shown). Furthermore, MCF7 A/Z MT cells or CHXpretreated control cells were stimulated with TNF-␣ in the presence of DMSO or z-IETD-fmk, and the kinetics of HER-2 protein degradation and PARP cleavage were compared. Fig. 5 , B and C, shows that in all of our experimental conditions, HER-2 and PARP cleavages occurred simultaneously and were inhibited similarly by the caspase-8 inhibitor. The efficiency of the z-IETD-fmk inhibitor was confirmed by Western blot analysis revealed with a caspase-8-specific antibody (data not shown).
Taken together, these data indicated that caspase-8 is responsible for the TNF-␣-induced HER-2 degradation in NFB-deficient cells.
Inhibition of Caspase-8-Mediated HER-2 Cleavage by NFBRegulated c-FLIP. Our data indicated that caspase-8-induced HER-2 cleavage only occurred in cells in which NFB activation or protein synthesis was inhibited. This cleavage is prevented in control cells through a TNF-␣-induced NFB pathway leading to the expression of caspase-inhibiting proteins.
To identify the protein products of these NFB-regulated genes, control and MT cells were treated with TNF-␣, and total cellular lysates were analyzed by Western blot analysis revealed with specific antibodies directed against well-known NFB-regulated caspase inhibitors. As shown in Fig. 6 , c-IAP-1, c-IAP-2, and XIAP protein levels were similar in untreated or TNF-␣-stimulated control or MT MCF7 A/Z cells. However, c-FLIP-L protein amounts were increased markedly in TNF-␣-stimulated control cells, whereas the expression of this protein decreased rapidly following treatment of MT cells (Fig. 6) .
Because c-FLIP-L is a well-known caspase-8 inhibitor and an NFB target gene product, we investigated whether modulation of its expression affects HER-2 cleavage (14, 54, 55) . Specific antisense oligonucleotides targeting c-flip mRNA efficiently decreased c-FLIP protein expression in control cells, whereas scrambled or sense oligonucleotides did not (Fig. 7A) . The inhibition of c-FLIP expression in control cells was correlated with TNF-␣-induced PARP cleavage and HER-2 degradation (Fig. 7A) . Interestingly, the inhibition of c-FLIP expression by the same antisense oligonucleotides also led to TNF-␣-induced HER-2 degradation in BT-474 and SKBR3 breast cancer cells, which are known to overexpress HER-2 (Fig. 7B) .
As additional evidence for c-FLIP-dependent inhibition of HER-2 cleavage, the opposite experiment was performed by reintroducing c-FLIP-L exogenous transient expression in IB␣ MT cells. We demonstrated that such ectopic c-FLIP expression partially inhibited TNF-␣-mediated HER-2 cleavage (Fig. 8) . IB␣ MT cells were transfected with either an empty vector or a c-FLIP expression vector and stimulated with TNF-␣. Cellular extracts then were analyzed by Western blot analysis for c-FLIP and HER-2 expression. In mocktransfected cells (Fig. 8A) , HER-2 completely disappeared after 16 h of TNF-␣ treatment, whereas it still could be observed in c-FLIPexpressing cells (Fig. 8B) .
These data clearly indicated that c-FLIP expression was induced through NFB activation in TNF-␣-stimulated control cells and that this protein inhibited the caspase-8-mediated HER-2 cleavage.
Identification of HER-2 Cleavage Sites Targeted by Caspase-8.
HER-2 degradation by caspase-8 did not generate any detectable cleavage product on immunoblot analyses performed with cellular extracts, even in the presence of proteasome inhibitors (data not shown). Therefore, HER-2 cleavage also was investigated in vitro. The HER-2 cytoplasmic domain was translated in vitro, and in vitro proteolysis assays were performed in the presence of hypotonic cellular extracts from control or MT cells, either untreated or TNF-␣ stimulated for 10 h. As shown in Fig. 9A, S 35 -labeled HER-2 COOHterminus domain was cleaved in two fragments after incubation with cellular extracts from TNF-␣-treated IB␣ MT cells. This cleavage was inhibited by preincubation of these extracts with the caspase-8 inhibitor, and similar cleavage fragments were generated after HER-2 COOH-terminus domain incubation with recombinant caspase-8 (Fig. 9A) .
We localized six potential caspase cleavage sites in the HER-2 COOH-terminal domain, and the aspartate residues from these sites were mutated into alanines (Fig. 9B) . The mutants MT1, MT2, and MT3 designated proteins where the residues 1012, 1019, and 1125 were mutated, respectively. In vitro proteolysis assays showed that the D1125A (MT3) mutant was partially resistant to proteolysis by recombinant caspase-8 (Fig. 9C) . Therefore, we proceeded with additional mutations and generated double mutants carrying the D1125A mutation plus a mutation of aspartate 837 (MT34), 1087 (MT35), or 1115 (MT36; Fig. 9B ). The double-mutant MT35, carrying D1125A and D1087A substitutions, was resistant completely to recombinant caspase-8-induced proteolysis (Fig. 9D) .
The wild-type and the HER-2 double mutants then were cloned into a pcDNA3 expression vector, and we verified that the mutated form was still uncleavable by recombinant caspase-8 during in vitro proteolysis assay (data not shown). The HER-2 wild-type and MT35 double mutant then were expressed exogenously in MCF7 A/Z IB␣ MT cells by transient transfection. Total cellular extracts from TNF-␣-treated cells were evaluated by immunoblot analyses, and these experiments showed that exogenously overexpressed wild-type HER-2 was cleaved partially in response to TNF-␣ treatment, whereas the MT35 mutant was not (Fig. 9E) .
Involvement of HER-2 Cleavage in TNF-␣-Induced Cell Death.
To test the biological significance of these observations, IB␣ MT MCF7 A/Z cells were transfected transiently with an empty expression vector, an expression vector coding for the wild-type HER-2, or with an expression vector coding for the MT35 HER-2. Cells then were stimulated for 2 days with TNF-␣ and living cells counted by trypan blue exclusion. As shown in Fig. 10A , most control pcDNA3-transfected cells were killed by TNF-␣ treatment. Exogenously expressed wild-type HER-2 clearly protected MCF7 A/Z cells from TNF-␣-induced cytotoxicity because the proportion of living cells was increased from 26 to 38% of the control. Interestingly, cell survival was additionally and reproducibly increased following exogenous expression of the MT35 HER-2 mutant (49% of the untreated control). These transfected cells also were pretreated with the anti-HER-2 monoclonal antibody trastuzumab before TNF-␣ stimulation. This antibody clearly suppressed HER-2-mediated cytoprotection against TNF-␣-induced cell death because it reduced the percentages of living cells to 26% after transfection of the wild-type HER-2 vector and to 30% after transfection of the mutated HER-2 vector (Fig. 10A) . For this experiment, transduction efficiency was controlled by transfecting in parallel an expression vector coding for the green fluorescent protein and counting positive cells by fluorescence-activated cell sorting. In representative experiments, ϳ50% of the cells were transfected (data not shown).
We checked that the increased living cell numbers were not related to HER-2-induced proliferation by measuring thymidine incorporation following transfection of MCF7 A/Z cells with the same expression vectors. As shown in Fig. 10B , there was not any significant difference in thymidine incorporation between control and HER-2-overexpressing cells.
These data proved that HER-2 expression protected IB␣ MT cells against TNF-␣-induced cell death. Therefore, the TNF-␣-mediated HER-2 cleavage in these cells may participate in the apoptotic pathway.
DISCUSSION
The apoptosis relies on the activity of caspases, a growing family of aspartyl-specific cysteine proteases that are essential for death-receptor proximal events and the execution of apoptosis by cleavage of broad-spectrum substrates. Among these "death substrates" are molecules involved in DNA repair like PARP, structural proteins, lamin, and focal adhesion kinase (56) , oncoproteins such as Bcl-2 (57), and signaling proteins (58) . Caspase-mediated cleavage of signaling molecules such as caspase-activated DNase (59, 60) , STAT-1 (61), Raf-1, Akt (62) , and c-Abl (63) leads to either their activation or inactivation. Because caspases are responsible for the onset of apoptosis, identification of their cellular substrates is essential and provides insights into the downstream events involved in apoptosis signaling. Among potential caspase substrates, a recent study showed that geldanamycin or staurosporin treatment of SKBR-3 human breast cancer cells led to HER-2 proteolytic cleavage, which was inhibited partially by a pleiotropic caspase inhibitor (53) . Our results clearly identified the oncoprotein HER-2 as a caspase-8 substrate. Interestingly, HER-2 cleavage by caspase-8 occurred early after TNF-␣ treatment, suggesting that this cleavage might be involved in proapoptotic signal progression.
It was reported previously that HER-2 proteolytic fragments were degraded rapidly but could be observed in the presence of proteasome inhibitors (55) . Nevertheless, in our experimental conditions, fragments derived from HER-2 cleavage were not detectable even in the presence of various protease inhibitors. Therefore, we decided to investigate HER-2 cleavage by in vitro proteolysis assays. This technique allowed us to observe cleaved fragments, identify two sites Western blot analysis was performed with total extracts (10 g) using anti-HER-2, anti-c-FLIP-L, and antiactin antibodies. Fig. 9 . Identification of the HER-2 cleavage sites. A, pcDNA3 and IB␣ MT MCF7 A/Z cells were stimulated with TNF-␣ (100 units/ml) for 10 h or left untreated, and hypotonic extracts were prepared. 35 S-labeled in vitro translated HER-2 COOH-terminus was incubated at 37°C for 2 h with either recombinant caspase-8 or hypotonic extracts in the presence or absence of caspase-8 inhibitor as indicated. Samples then were separated using SDS-PAGE. Cleaved bands are marked with an arrow. B, schematic representation of the in vitro mutagenesis performed using the HER-2 COOH-terminus template. White rectangles represent the COOH-terminal part of HER-2. Black squares and numbers indicate the aspartate to alanine substitutions. C and D, wild-type (WT), single-mutant (MT; C), or double-mutant (D) 35 S-labeled in vitro translated HER-2 C-termini were loaded untreated or were incubated with recombinant caspase-8 for 2 h at 37°C. Samples then were separated using SDS-PAGE. Arrows indicate the cleaved bands. E, IB␣ MT MCF7 A/Z cells were transfected with expression vectors encoding wild-type HER-2 (HER-2WT) or the double-mutant 35 (HER-2MT35). Eight h after transfection, cells were stimulated by TNF-␣ (100 units/ml), and total extracts (10 g) were analyzed by Western blot analysis using specific anti-HER-2 and antiactin antibodies.
targeted by caspase-8, and generate a mutant resistant to proteolytic cleavage in vitro and in cells.
It was shown previously that TNF-␣ treatment led to a decrease in HER-2 mRNA synthesis (64) or in protein level expression (65) . We did not observe any effect of TNF-␣ on HER-2 transcription level. These discrepancies probably rely on differences in cellular models. Nevertheless, for the first time, we report a caspase-dependent cleavage of the HER-2 protein following TNF-␣ treatment.
HER-2 expression enhances proliferative, metastatic, and prosurvival signals in breast cancer cells and is correlated with a poor prognosis in breast and ovarian adenocarcinomas (39 -41) . Furthermore, HER-2 expression induces a resistance to cancer therapy, and its inhibition by a specific antibody, trastuzumab, has clinical activity either alone or in combination with chemotherapy in HER-2-expressing breast cancers (45) (46) (47) (48) (49) . Moreover, it has been demonstrated that HER-2 overexpression can induce resistance to TNF-␣ stimulation (43) and that trastuzumab can restore the cytotoxic response (50) . Our results raise the hypothesis that a caspase-8-mediated HER-2 cleavage following TNF-␣ stimulation could participate in the subsequent apoptosis. Overexpression of a wild-type HER-2 protein significantly inhibits TNF-␣-induced cell death, and survival is further increased following overexpression of an uncleavable HER-2 protein, demonstrating that HER-2 cleavage contributes to apoptosis.
HER-2 expression inhibits cell death by inducing antiapoptotic pathways, such as Bcl-2 and Bcl-XL up-regulation (66), or by activation of the Akt/NFB prosurvival cascade (67) (68) (69) . NFB is an extensively described antiapoptotic transcription factor whose nuclear DNA binding is potently and rapidly induced by TNF-␣ in almost all of the cell lines (70) . Constitutive NFB activation has been observed in a wide variety of cancers and is associated with a resistance to apoptosis because many of its target genes code for antiapoptotic molecules (10 -25) . In our model, TNF-␣ stimulation leads to NFB activation and subsequent expression of one of its target genes, c-FLIP (14, 54) . c-FLIP is a caspase-8 inhibitor and therefore counteracts HER-2 cleavage triggered by TNF-␣ stimulation (55) . This c-FLIP-mediated cleavage inhibition does not occur when NFB activity is blocked by IB␣ MT expression or a chemical inhibitor like BAY 11-7085, demonstrating that it requires the integrity of the NFB pathway.
Because we demonstrated that HER-2 cleavage might participate in TNF-␣-induced apoptosis, our results suggest that NFB-dependent inhibition of HER-2 cleavage is a novel mechanism for NFB antiapoptotic role. Interestingly, we also observed a HER-2 cleavage in response to daunorubicin through an NFB-independent mechanism, suggesting that this cleavage could be a general feature of apoptosis. 3 These results currently are under investigation.
In conclusion, we provide evidence, for the first time, that caspase-8 cleaves the HER-2 oncoprotein in response to TNF-␣ stimulation, and we propose an original model in which NFB exerts a new antiapoptotic function through c-FLIP-induced expression and subsequent inhibition of TNF-␣-triggered cleavage of the HER-2 survival factor (Fig. 11) . Therefore, this antiapoptotic mechanism 3 Unpublished observations. underlines the opportunity to evaluate the NFB activation status and the HER-2 expression level in breast cancer cells and opens new ways to develop combined anticancer therapies for HER-2-overexpressing cancers. Because NFB inhibitors currently are being evaluated as anticancer therapeutic agents, our results indicate a putative novel activity for these agents. Anti-HER-2 antibodies and NFB inhibitors possibly may be combined with chemotherapy or biological modifiers for the management of HER-2-overexpressing cancers. It also would be most interesting to determine whether a similar effect could be observed with other receptors belonging to the EGFR family.
